The U.S. Food and Drug Administration Approves Epcoritamab-bysp (Epkinly) for Diffuse Large B-Cell Lymphoma
On May 19, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved…
Lymphoma News
The U.S. Food and Drug Administration Approves Polatuzumab Vedotin-piiq (Polivy) for Diffuse Large B-Cell Lymphoma
On April 19, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved polatuzumab…
Update on AbbVie Withdrawal of Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications
On April 6, 2023, AbbVie announced its intent to withdraw the accelerated approval of ibrutinib…
The U.S. Food and Drug Administration Approves Pirtobrutinib (Jaypirca) for Relapsed/Refractory Mantle Cell Lymphoma
On January 27, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved pirtobrutinib…
The U.S. Food and Drug Administration Approves Zanubrutinib (Brukinsa) for Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL)
On January 19, the U.S. Food and Drug Administration (FDA) announced it has approved bruton tyrosine…
The U.S. Food and Drug Administration Approves Mosunetuzumab-axgb (Lunsumio) for Follicular Lymphoma
On December 22, 2022, the U.S. Food and Drug Administration (FDA) announced it has approved…
Mobile Health Technology Helps Blood Cancer Patients Navigate Diagnosis
These days, a cellphone is much more than just a phone – it’s a photo album, a GPS, a stereo system, an encyclopedia, a computer, a gaming system, a suite of tools all in the palm of your hand. One of the many tools that can be accessed via mobile technology are apps intended to help manage your health, sometimes known as mobile health technology.
The U.S. Food and Drug Administration Approves Brentuximab Vedotin (Adcetris) for Hodgkin Lymphoma
On November 11, 2022, the U.S. Food and Drug Administration (FDA) announced it has approved the use of brentuximab vedotin (Adcetris), for pediatric patients 2 years of age and older with previously untreated high-risk classical Hodgkin lymphoma (cHL).
U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (BREYANZI) for Large B-Cell Lymphoma
The U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma On…
U.S. Food and Drug Administration Approves CAR T Cell Therapy for Follicular Lymphoma
FDA announced it has approved the use of tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Stay informed with news, alerts and other resources.
